Prospective Study of the Use of Thalidomide in Patients With Arachnoiditis
Arachnoiditis, a neuropathic disease caused by inflamation of the arachnoid membrane that
surrounds and protects the spinal nerves,can result in a debilitating state that is
characterized by numbing and tingling, stinging and burning in the lower back or legs, and
possible muscle cramps, twitching and spasms. Current treatments are not always effective in
treating the pain associated with arachnoiditis. Recent research has indicated that a group
of chemicals called cytokines that are produced by various cells in the body may be
responsible for generating the pain response. Medications that effect the release of
cytokines or block the action of cytokines may reduce the pain response. Various
anti-cytokine medications are now being used to treat painful disease states such as
rheumotoid arthritis and Crohn's Disease. In this study the anti-cytokine medication,
Thalidomide, is being evaluated for it's effect in treating pain associated with
arachnoiditis.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
1. To evaluate the change in pain as measured by the McGill Pain Questionnaire, short form, (SF-MPQ) and consumption of adjuvant opioid medications in three patients with arachnoiditis who receive thalidomide.
Anthony H Guarino, MD
Principal Investigator
Washington University in St. Louis
United States: Food and Drug Administration
CG0678
NCT00284505
July 2005
July 2006
Name | Location |
---|---|
Washington University Pain Management Center | St. Louis, Missouri 63141 |